Inflammatory pain in the rabbit: A new, efficient method for measuring mechanical hyperalgesia in the hind paw

被引:16
作者
Dong, Hong [1 ]
Sun, Hong [1 ]
Magal, Ella [1 ]
Ding, Xiao [2 ]
Kumar, Gondi N. [2 ]
Chen, Jian Jeffrey [3 ]
Johnson, Eileen J. [1 ]
Manning, Barton H. [1 ]
机构
[1] Amgen Inc, Dept Neurosci, Thousand Oaks, CA 91320 USA
[2] Amgen Inc, Dept Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA
[3] Amgen Inc, Dept Small Mol Chem, Thousand Oaks, CA 91320 USA
关键词
opioid; morphine; NSAID; indomethacin; bradykinin B-1; B-2; Electrovonfrey (R); carrageenan; des-Arg(10); Leu9]-kallidin; HOE; 140;
D O I
10.1016/j.jneumeth.2007.09.028
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The discovery of novel analgesic Compounds that target some receptors can be challenging due to species differences in ligand pharmacology. If a putative analgesic compound has markedly lower affinity for rodent versus other mammalian orthologs of a receptor, the evaluation of antinociceptive efficacy in non-rodent species becomes necessary. Here, we describe a new, efficient method for measuring inflammation-associated nociception in conscious rabbits. An electronic von Frey device is used, consisting of a rigid plastic tip connected to a force transducer in a hand-held probe. The plastic tip is applied to the plantar surface of a hind paw with increasing force until a withdrawal response is observed. The maximum force (g) tolerated by the rabbit (i.e., withdrawal threshold) is recorded. In young, conscious rabbits (500-700 g), baseline hind paw withdrawal thresholds typically fell within the 60-80 g range. Three hours after injection of the inflammatory agent carrageenan (3%, 200 mu L, intra-plantar), withdrawal thresholds dropped by similar to 30-40 a, indicating the presence of punctate mechanical hyperalgesia. The development of hyperalgesia was dose dependently prevented by the NSAID indomethacin (ED50 = 2.56 mg/kg, p.o.) or the bradykinin B-2 receptor peptide antagonist HOE 140 (intra-paw administration). An established hyperalgesia was dose dependently reversed by morphine sulfate (ED50 = 0.096 mg/kg, s.c.) or the bradykinin B-1 receptor peptide antagonist [des-Arg(10),Leu(9)]-kallidin (ED50 = 0.45 mg/kg, s.c.). Rabbits treated with the novel B I receptor small molecule antagonist compound A also showed dose-dependent reversal of hyperalgesia (ED50 = 20.19 mg/kg, s.c.) and analysis of plasma samples taken from these rabbits showed that, unlike other rabbit pain models, the current method permits the evaluation of pharmacokinetic-pharmacodynamic (PK-PD) relationships (compound A plasma EC50 = 402.6 nM). We conclude that the Electrovonfrey (R) method can be used in rabbits with inflammatory pain to generate reliable dose- and plasma concentration-effect curves for different classes of analgesics. (c) 2007 Published by Elsevier B.V..
引用
收藏
页码:76 / 87
页数:12
相关论文
共 51 条
[31]   The bradykinin B1 receptor antagonist B9858 inhibits a nociceptive spinal reflex in rabbits [J].
Mason, GS ;
Cumberbatch, MJ ;
Hill, RG ;
Rupniak, NMJ .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2002, 80 (04) :264-268
[32]   Deconstructing endogenous pain modulation [J].
Mason, P .
JOURNAL OF NEUROPHYSIOLOGY, 2005, 94 (03) :1659-1663
[33]   Mutagenesis at the human tachykinin NK2 receptor to define the binding site of a novel class of antagonists [J].
Meini, S ;
Bellucci, F ;
Catalani, C ;
Cucchi, P ;
Patacchini, R ;
Rotondaro, L ;
Altamura, M ;
Giuliani, S ;
Giolitti, A ;
Maggi, CA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 488 (1-3) :61-69
[34]   Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors [J].
Mukherjee, S ;
Adams, M ;
Whiteaker, K ;
Daza, A ;
Kage, K ;
Cassar, S ;
Meyer, M ;
Yao, BB .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 505 (1-3) :1-9
[35]  
PRADIER L, 1995, MOL PHARMACOL, V47, P314
[36]   Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist [J].
Ransom, RW ;
Harrell, CM ;
Reiss, DR ;
Murphy, KL ;
Chang, RSL ;
Hess, JF ;
Miller, PJ ;
O'Malley, SS ;
Hey, PJ ;
Kunapuli, P ;
Su, DS ;
Markowitz, MK ;
Wallace, MA ;
Raab, CE ;
Jones, AN ;
Dean, DC ;
Pettibone, DJ ;
Freidinger, RM ;
Bock, MG .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 499 (1-2) :77-84
[37]   PHARMACOLOGICAL DIFFERENCES BETWEEN RAT AND HUMAN ENDOTHELIN-B RECEPTORS [J].
REYNOLDS, EE ;
HWANG, O ;
FLYNN, MA ;
WELCH, KM ;
CODY, WL ;
STEINBAUGH, B ;
HE, JX ;
CHUNG, FZ ;
DOHERTY, AM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 209 (02) :506-512
[38]   Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters [J].
Roman, DL ;
Saldaña, SN ;
Nichols, DE ;
Carroll, FI ;
Barker, EL .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (02) :679-687
[39]   Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils [J].
Rupniak, NMJ ;
Carlson, E ;
Boyce, S ;
Webb, JK ;
Hill, RG .
PAIN, 1996, 67 (01) :189-195
[40]   MODIFICATION OF RHYTHMICAL JAW MOVEMENTS BY NOXIOUS PRESSURE APPLIED TO THE PERIOSTEUM OF THE ZYGOMA IN DECEREBRATE RABBITS [J].
SCHWARTZ, G ;
LUND, JP .
PAIN, 1995, 63 (02) :153-161